Published in Lancet Oncol on November 09, 2010
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Gallbladder cancer: expert consensus statement. HPB (Oxford) (2015) 1.10
Gallbladder Cancer in the 21st Century. J Oncol (2015) 1.02
Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol (2012) 0.97
Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med (2011) 0.93
Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer Res (2011) 0.92
Current status of chemotherapy for the treatment of advanced biliary tract cancer. Korean J Intern Med (2013) 0.92
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat (2015) 0.90
Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World J Clin Oncol (2011) 0.88
A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother (2013) 0.88
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget (2016) 0.87
Current therapy and future directions in biliary tract malignancies. Curr Treat Options Oncol (2013) 0.86
New and emerging treatment options for biliary tract cancer. Onco Targets Ther (2013) 0.85
Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol (2013) 0.84
Tumors of ampulla of Vater: A case series and review of chemotherapy options. World J Gastrointest Oncol (2012) 0.84
Molecular Targets in Biliary Carcinogenesis and Implications for Therapy. Oncologist (2015) 0.83
Targeted Therapy in Biliary Tract Cancers. Curr Treat Options Oncol (2015) 0.83
AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther (2013) 0.83
Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma. BMC Cancer (2013) 0.82
Beclin 1 deficiency correlated with lymph node metastasis, predicts a distinct outcome in intrahepatic and extrahepatic cholangiocarcinoma. PLoS One (2013) 0.82
Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. ISRN Hepatol (2014) 0.81
A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepat Oncol (2014) 0.81
Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. Transl Oncol (2015) 0.80
Optimum chemotherapy for the management of advanced biliary tract cancer. World J Gastroenterol (2015) 0.80
Targeted therapy for biliary tract cancer. Cancers (Basel) (2011) 0.80
Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma. J Gastrointest Surg (2012) 0.79
Synchronous double primary cancer - intrahepatic cholangiocarcinoma with bone metastases and thyroid carcinoma: A case report. Oncol Lett (2015) 0.79
A pathologic complete response in the surgical specimen after systemic chemotherapy for a gallbladder carcinoma. Gastrointest Cancer Res (2012) 0.79
Current status of immunotherapy for the treatment of biliary tract cancer. Hum Vaccin Immunother (2013) 0.79
A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs (2016) 0.79
Clinical effect of a positive surgical margin after hepatectomy on survival of patients with intrahepatic cholangiocarcinoma. Drug Des Devel Ther (2014) 0.78
Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer. Onco Targets Ther (2015) 0.78
Chemotherapy and targeted therapy for gall bladder cancer. Indian J Surg Oncol (2014) 0.77
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. Br J Cancer (2014) 0.77
Metal stents: a bridge to surgery in hilar cholangiocarcinoma. HPB (Oxford) (2012) 0.77
Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev (2016) 0.76
Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol (2016) 0.75
Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res (2013) 0.75
Systemic Therapy of Cholangiocarcinoma. Visc Med (2016) 0.75
PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. Oncotarget (2015) 0.75
Progression of targeted therapy in advanced cholangiocarcinoma. Chin J Cancer Res (2015) 0.75
High Uptake of FDG Along a Biliary Stent. Clin Nucl Med (2016) 0.75
Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis. Onco Targets Ther (2016) 0.75
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. PLoS One (2015) 0.75
Multidisciplinary collaboration in gallbladder carcinoma treatment: A case report and literature review. Oncol Lett (2016) 0.75
Targeting interleukin-4 receptor alpha by hybrid Peptide for novel biliary tract cancer therapy. Int J Hepatol (2014) 0.75
Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States. J Gastrointest Oncol (2016) 0.75
Biliary cancers, chemotherapy, and cetuximab. Lancet Oncol (2010) 0.75
Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol (2017) 0.75
Immunotherapeutic Approaches to Biliary Cancer. Curr Treat Options Oncol (2017) 0.75
Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma. World J Surg (2017) 0.75
Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol (2017) 0.75
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol (2009) 5.57
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology (2014) 4.00
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol (2008) 3.09
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol (2006) 2.51
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res (2009) 2.30
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol (2010) 1.80
Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol (2011) 1.78
Laryngeal recurrent nerve injury in surgery for benign thyroid diseases: effect of nerve dissection and impact of individual surgeon in more than 27,000 nerves at risk. Ann Surg (2002) 1.69
Hypoparathyroidism after total thyroidectomy: a prospective study. Arch Surg (2008) 1.63
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer (2007) 1.58
Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. Arch Pathol Lab Med (2012) 1.53
Current value of intraoperative sonography during surgery for hepatic neoplasms. World J Surg (2002) 1.48
Accuracy of multiphasic helical computed tomography and intraoperative sonography in patients undergoing orthotopic liver transplantation for hepatoma: what is the truth? Ann Surg (2002) 1.44
Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol (2008) 1.39
c-kit overexpression in chromophobe renal cell carcinoma is not associated with c-kit mutation of exons 9 and 11. Am J Surg Pathol (2005) 1.39
High-risk human papilloma virus infection of the foreskin in asymptomatic boys. Urology (2013) 1.39
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol (2010) 1.36
The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res (2002) 1.35
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol (2010) 1.32
Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation (2007) 1.29
Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med (2011) 1.28
Hepatocellular carcinoma--survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int (2005) 1.28
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer (2008) 1.26
Band slippage--a potentially life-threatening complication after laparoscopic adjustable gastric banding. Obes Surg (2005) 1.22
Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. Pediatr Res (2005) 1.21
Surgery for gastrointestinal stromal tumors of the stomach. J Gastrointest Surg (2009) 1.18
Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin Gastroenterol Hepatol (2005) 1.17
Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol (2010) 1.16
Thyroid surgery in the geriatric patient. Arch Surg (2002) 1.13
Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood (2002) 1.12
Balance between NF-kappaB and JNK/AP-1 activity controls dendritic cell life and death. Blood (2005) 1.12
Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol (2010) 1.10
Parathyroid hormone monitoring during total parathyroidectomy for renal hyperparathyroidism: pilot study of the impact of renal function and assay specificity. Clin Chem (2006) 1.08
A "defined baseline" in PTH monitoring increases surgical success in patients with multiple gland disease. Surgery (2007) 1.08
Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med (2005) 1.07
Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.07
Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg (2006) 1.07
Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res (2007) 1.04
Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology (2011) 1.04
Weight loss reduces tissue factor in morbidly obese patients. Obes Res (2003) 1.02
KiSS-1 overexpression as an independent prognostic marker in hepatocellular carcinoma: an immunohistochemical study. Virchows Arch (2007) 1.01
MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1. Clin Cancer Res (2012) 1.00
NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J Hepatol (2006) 0.98
Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol (2010) 0.98
Videoendoscopy and histopathology of the esophagogastric junction in patients with gastroesophageal reflux disease. Wien Klin Wochenschr (2007) 0.97
Multiple chromosomal abnormalities in human liver (pre)neoplasia. J Hepatol (2004) 0.96
Hepatocyte GP73 expression in Wilson disease. J Hepatol (2009) 0.96
PTH spikes during parathyroid exploration--a possible pitfall during PTH monitoring? Langenbecks Arch Surg (2006) 0.96
Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol (2010) 0.95
Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. Ann Surg Oncol (2011) 0.95
Impact of localization studies on feasibility of minimally invasive parathyroidectomy in an endemic goiter region. J Am Coll Surg (2003) 0.94
6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol (2007) 0.94
Applicability of laparoscopic adrenalectomy in a prospective study in 150 consecutive patients. Arch Surg (2004) 0.93
Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg (2010) 0.92
HPV infection and p16 expression in carcinomas of the minor salivary glands. Eur Arch Otorhinolaryngol (2011) 0.92
Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection. Ann Surg Oncol (2011) 0.92
Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy. Eur J Radiol (2009) 0.91
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Mol Cancer Ther (2009) 0.91
Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial. BMC Anesthesiol (2009) 0.91
Complications after free flap surgery: do we need a standardized classification of surgical complications? Br J Oral Maxillofac Surg (2011) 0.91
Quantitative analysis of gene expression in human articular chondrocytes in monolayer culture. Int J Mol Med (2004) 0.91
Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels. Clin Cancer Res (2008) 0.90
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. Oncol Rep (2008) 0.90
Post-treatment imaging of liver tumours. Cancer Imaging (2007) 0.89
Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol (2012) 0.89
Treatment and outcome of intrahepatic cholangiocellular carcinoma. Am J Surg (2005) 0.89
Therapeutic efficacy of polyclonal tregs does not require rapamycin in a low-dose irradiation bone marrow transplantation model. Transplantation (2011) 0.88
The high affinity IgE receptor Fc epsilonRI is expressed by human intestinal epithelial cells. PLoS One (2010) 0.88
Intermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer. PLoS One (2012) 0.88
The value of intraoperative pentagastrin testing in medullary thyroid cancer. Surgery (2007) 0.88
Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Appl Immunohistochem Mol Morphol (2013) 0.87
Parathyroidectomy improves concentration and retentiveness in patients with primary hyperparathyroidism. Surgery (2002) 0.87
Diagnostic significance of aquaporin-1 in liver tumors. Hum Pathol (2005) 0.87
Desmoplastic stromal reaction in medullary thyroid cancer-an intraoperative "marker" for lymph node metastases. World J Surg (2006) 0.87
Adequate preoperative staging rarely leads to a change of intraoperative strategy in patients undergoing surgery for colorectal cancer liver metastases. Surgery (2008) 0.86
Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology (2014) 0.86
Impact of the reconstruction method on delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: a prospective randomized study. World J Surg (2014) 0.86
Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases. Ann Surg Oncol (2012) 0.86
Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors. Int J Oncol (2010) 0.85
Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. Wien Klin Wochenschr (2011) 0.85
Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell transplantation. Virchows Arch (2014) 0.84
Perioperative GLY-GLN infusion diminishes the surgery-induced period of immunosuppression: accelerated restoration of the lipopolysaccharide-stimulated tumor necrosis factor-alpha response. Ann Surg (2003) 0.84
Histopathology of the endoscopic esophagogastric junction in patients with gastroesophageal reflux disease. Wien Klin Wochenschr (2008) 0.84
Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing. Eur J Immunol (2003) 0.84